A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

NCT05809934 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

220

Enrollment

INDUSTRY

Sponsor class

Conditions

Nonalcoholic Steatohepatitis

Interventions

DRUG: AZD2693
OTHER: Placebo

Sponsor

AstraZeneca